New Epstein-Barr Virus Study Results from Shandong Provincial Hospital Affiliated to Shandong First Medical University Described (Umbilical Cord Blood Stem Cells As Third-Party Adjuvant Infusion in Human Leukocyte Antigen Antibody-Positive...).

A recent study conducted at Shandong Provincial Hospital in China explored the use of umbilical cord blood stem cells as a third-party adjuvant infusion in patients with human leukocyte antigen (HLA) antibodies undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study found that patients receiving the umbilical cord blood stem cells had a lower incidence of Epstein-Barr virus (EBV) reactivation compared to those without the infusion. Additionally, patients without HLA antibodies had higher one-year relapse-free survival and lower one-year transplantation-related mortality. The study suggests that this approach may be safe and beneficial for patients with HLA antibodies, but further research is needed to validate these results. [Extracted from the article]